Intuitive Surgical, Inc.

ISRG · NASDAQ · USD

Can Intuitive offset slower United States procedure growth and deliberate instrument price cuts with international adoption, capital placements and new procedures?

Last 4 earnings calls · through Q3 FY2026

Bull case

  • International benign procedure adoption

    The bull case is that adoption abroad is still early, and wider use in hernia and gallbladder surgery keeps international growth well ahead of the United States.

  • Capital demand and installed base

    Demand for the newest multiport system and for refurbished prior-generation machines is adding hospital capacity, and management expects the upgrade cycle to run for years.

  • Clinical evidence for robotic surgery

    Large published analyses showing fewer conversions to open surgery give hospital administrators the evidence they need to justify building and expanding robotic programs.

  • Pricing to widen access

    Deliberate instrument price cuts are meant to make robotic surgery affordable in high-volume, cost-sensitive procedures, trading revenue per case for a larger patient pool.

Bear case

  • Slowing United States procedures

    The bear case is that United States procedure growth has slowed as patients defer elective benign care, and it is unclear how much of that volume comes back.

  • Lower instrument revenue per case

    Instrument price reductions and a mandated cut in China lower what Intuitive earns per procedure, so procedure growth has to carry more of the revenue burden.

  • China tenders and local suppliers

    Chinese policy favors domestic robot makers and centralized tenders, and Intuitive placed very few systems there while its newest platforms await clearance.

  • Cheaper systems hold prices flat

    Refurbished and prior-generation systems are winning placements across cost-sensitive markets, which holds average selling prices flat even as the flagship model improves.

Bull and bear points

Growth & Execution

In short: International procedures and capital demand are strong, while United States procedure growth has slowed.

Bull · 3

  • International benign procedures grew 41% in Q3

    Benign general surgery outside the United States is the largest untapped part of the business, and hernia repair and gallbladder removal are where hospital adoption is compounding fastest.

    Q3 FY2026 call

  • Net system placements grew 40% in the quarter

    Systems revenue rose 30.3% year over year, and placements that add capacity rather than replace machines create the procedure volume that future instrument sales depend on.

    Q3 FY2026 call

  • Procedure guidance raised and narrowed for 2026

    In January management guided da Vinci procedure growth of 13% to 15% for 2026; it now expects 14% to 15% and closer to the midpoint, even with a softer United States trend.

    Tone shiftQ4 FY2025 → Q3 FY2026
Bear · 2

  • United States procedure growth slowed to 10% in Q3

    Management links part of the moderation to patients deferring care after premium subsidies expired, and it is watching Medicaid eligibility and 340B changes for further effects.

    Q3 FY2026 call

  • Bariatric volumes keep shrinking with GLP-1 use

    Weight-loss drug adoption has cut a procedure category that uses the robot heavily, and United States bariatric cases have posted high single-digit declines across recent quarters.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins and cash generation are strong, while planned instrument price cuts will trim revenue per case.

Bull · 2

  • Gross margin improved two points year over year

    Product cost reductions and leverage of fixed factory overhead are offsetting tariffs and the higher cost of building newer platforms, keeping more of each revenue dollar.

    Filed financials

  • Free cash flow reached 31% of revenue

    Cash conversion at that level funds research spending, the planned Malaysian instrument plant and large share repurchases without adding debt to the balance sheet.

    Filed financials
Bear · 2

  • Instrument prices are being cut on purpose

    Management previously described innovation as a route to higher pricing; it now plans to lower instrument cost per procedure by 3% to 5%, with China adding a further reduction.

    Tone shiftQ1 FY2026 → Q3 FY2026

  • Reported operating margin fell on a legal charge

    The settlement with United States customers over third-party instrument remanufacturing and servicing sits in the quarter's results; excluding it, management reported margins of about 41%.

    Q3 FY2026 call

Market Position

In short: A tiered system portfolio and clinical evidence help, while Chinese policy and local rivals pressure pricing.

Bull · 2

  • A tiered system lineup covers several price points

    Selling refurbished and prior-generation systems alongside the newest model lets Intuitive compete for cost-constrained hospitals and surgery centers instead of losing those customers.

    Q3 FY2026 call

  • Published evidence shows fewer open conversions

    A meta-analysis covering about 1.5 million da Vinci patients found 54% lower odds of converting to open surgery than with laparoscopy, which is the case hospitals make internally.

    Q3 FY2026 call
Bear · 2

  • China pricing turns against Intuitive

    Management once said it could compete with local robot makers at a healthy price; provincial charge-code changes now force a significant cut to instrument prices there from November.

    Tone shiftQ4 FY2025 → Q3 FY2026

  • Cheaper system mix holds selling prices flat

    As refurbished and prior-generation machines take a larger share of placements, system pricing stays level and the benefit of a richer flagship mix does not reach revenue.

    Q3 FY2026 call